Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.65 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | INSR | P06213 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | PLK1 | P53350 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28407550 | 0.92 | EGFR (0.80) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL3319934 | 0.91 | EGFR (0.79) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL12093969 | 0.91 | EGFR (0.75) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL9910672 | 0.90 | EGFR (0.86) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL9910673 | 0.89 | EGFR (0.76) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL13889686 | 0.89 | EGFR (0.61) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL233913 | 0.89 | EGFR (0.77) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL15928184 | 0.88 | EGFR (0.72) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL15928201 | 0.88 | EGFR (0.72) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL12093971 | 0.88 | EGFR (0.75) | EGFRGAKERBB2ERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-7754729-B2 | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-07-13 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | ABL1, MAP3K7, MAP3K5 | EGFR 616/4885GAK 114/4885ERBB2 199/4885 |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885GAK 390/4885ERBB2 170/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885GAK 390/4885ERBB2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.